Regulus Therapeutics Newsroom

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

PR NewswireNov 26 21:00

Oppenheimer Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $7

Futu NewsNov 12 21:31 · Ratings

Regulus Therapeutics Poised for Growth: Promising ADPKD Study Results and Strategic Milestones Drive Buy Rating

TipRanksNov 11 19:37 · Ratings

Buy Rating for Regulus Therapeutics Driven by Promising Clinical and Regulatory Prospects for RGLS8429

TipRanksNov 11 14:26 · Ratings

Regulus Therapeutics GAAP EPS of -$0.21 Misses by $0.04

Seeking AlphaNov 8 07:11

Regulus Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 8 05:33 · Announcements

Regulus Therapeutics | 8-K: Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

SECNov 8 05:22

Express News | Regulus Therapeutics Q3 Income From Operations USD -15.21 Million

BreakingsNov 8 05:05

Press Release: Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

Dow JonesNov 8 05:05

Regulus Therapeutics 3Q Loss/Shr 21c >RGLS

Dow JonesNov 8 05:05

Watching Regulus Therapeutics; Shares See Volume To The Upside As Traders Circulate TipRanks Article Titled 'These 2 'Strong Buy' Penny Stocks Could Rally Over 500%, Say Analysts'

BenzingaOct 28 23:22

Regulus Therapeutics Completes Enrollment in Phase 1b Kidney Disease Drug Trial

MT NewswiresOct 8 23:32

H.C. Wainwright Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $10

Futu NewsOct 8 22:31 · Ratings

Express News | Regulus Therapeutics Inc: Remain on Track for an End of Phase 1 Meeting With FDA by End of 2024

BreakingsOct 8 20:01

Express News | Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Rgls8429 for the Treatment of Patients With Autosomal Dominant Polycystic Kidney Disease (Adpkd)

BreakingsOct 8 20:00

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Yahoo FinanceOct 8 20:00

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

newsfilter.ioAug 28 20:00

Oppenheimer Reiterates Outperform on Regulus Therapeutics, Maintains $7 Price Target

BenzingaAug 15 01:36 · Ratings

HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $10 Price Target

BenzingaAug 10 05:26 · Ratings

Regulus Therapeutics Analyst Ratings

BenzingaAug 10 05:24 · Ratings